Depósito Digital de Documentos de la UAB Encontrados 5 registros  La búsqueda tardó 0.01 segundos. 
1.
13 p, 1.6 MB Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers / Fucà, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Cohen, Romain (Hôpital Saint-Antoine) ; Lonardi, Sara (Istituto Oncologico Veneto IOV-IRCSS) ; Shitara, Kohei (National Cancer Center Hospital East) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope Comprehensive Cancer Center) ; Chao, Joseph (City of Hope Comprehensive Cancer Center) ; Klempner, Samuel J. (Harvard Medical School) ; Emmett, Matthew (Harvard Medical School) ; Jayachandran, Priya (University of Southern California) ; Bergamo, Francesca (Istituto Oncologico Veneto IOV-IRCSS) ; García, Marc Díez (Vall d'Hebron Institut d'Oncologia) ; Mazzoli, Giacomo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Provenzano, Leonardo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Colle, Raphael (Hôpital Saint-Antoine) ; Svrcek, Magali (Hôpital Saint-Antoine, AP-HP, and INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer) ; Ambrosini, Margherita (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Randon, Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Shah, Aakash Tushar (Baylor College of Medicine) ; Salati, Massimiliano (University Hospital of Modena) ; Fenocchio, Elisabetta (Candiolo Cancer Institute FPO-IRCCS) ; Salvatore, Lisa (Fondazione Policlinico Universitario Agostino Gemelli IRCCS) ; Chida, Keigo (National Cancer Center Hospital East) ; Kawazoe, Akihito (National Cancer Center Hospital East) ; Conca, Veronica (University of Pisa) ; Curigliano, Giuseppe (University of Milan) ; Corti, Francesca (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Cremolini, Chiara (University of Pisa) ; Overman, Michael (University of Texas MD Anderson Cancer Center) ; André, Thierry (Hôpital Saint-Antoine) ; Pietrantonio, Filippo (Fondazione IRCCS Istituto Nazionale dei Tumori) ; Universitat Autònoma de Barcelona
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. [...]
2022 - 10.1136/jitc-2021-004001
Journal for immunotherapy of cancer, Vol. 10 (february 2022)  
2.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D. C. (The West Clinic, Memphis, USA) ; Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K. (Aichi Cancer Center Hospital) ; Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A. (Mayo Clinic, Phoenix, USA) ; O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ; Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
3.
9 p, 325.6 KB Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ; Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ; Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ; Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ; Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ; Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ; Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ; Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ; Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ; Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Taniguchi, H. (Aichi Cancer Center Hospital) ; Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ; Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ; Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ; Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ; Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ; Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963  
4.
16 p, 1.5 MB Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses / Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East) ; Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS) ; Falcone, Alfredo (Department of Oncology. University of Pisa) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS) ; Hastedt, Claudia (Boehringer Ingelheim International GmbH) ; Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Griebsch, Ingolf (Boehringer Ingelheim International GmbH) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Universitat Autònoma de Barcelona
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. [...]
2019 - 10.1016/j.clcc.2019.08.005
Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5  
5.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Van Cutsem, E. (University Hospitals Leuven (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. L. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.